Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.06) by 22.81 percent. This is a 74.07 percent increase over losses of $(0.27) per share from the same period last year. The company reported quarterly sales of $1.461 million which missed the analyst consensus estimate of $5.000 million by 70.78 percent. This is a 42.12 percent increase over sales of $1.028 million the same period last year.